Tag: HCC

This advertorial is sponsored by Sirtex Medical, is only available in selected countries and geographies. The SUMM90YT conference (23 February, Frankfurt, Germany)—hosted by Sirtex—gathered leading...

This advertorial, sponsored by Varian, is only available in selected countries and geographies. In the realm of interventional radiology (IR), technological advancements and innovation are...

This advertorial is sponsored by Sirtex Medical. Highlights:  This four-page supplement shares insights given by key opinion leaders in selective internal radiation therapy (SIRT) using SIR-Spheres...

This advertorial is sponsored by Sirtex.  Interventional radiologists Thomas Albrecht (Vivantes Clinic Neukölln, Berlin, Germany) and Roberto Iezzi (Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy)...

In the final months of 2023, the Addenbrooke Hospital in Cambridge, UK, were reported as the first UK National Health Service (NHS) facility to...

TriSalus Life Sciences, an oncology company integrating delivery technology with immunotherapy in the treatment of patients with liver and pancreatic tumours, today announced the...

ABK Biomedical, a medical device company dedicated to the research, development, and commercialisation of advanced imageable embolic medical devices, has announced the first...

This advertorial is sponsored by Terumo Interventional Systems LifePearl™ microspheres (Terumo) are polyethylene glycol (PEG) embolization microspheres that can be loaded with chemotherapeutic drugs including...

ABK Biomedical has received approval for its investigational device exemption (IDE) application from the US Food and Drug Administration (FDA) to commence a multicentre...

Day two of the European Conference on Interventional Oncology (ECIO; 16–19 April, Stockholm, Sweden) opened with a session dedicated to posing and responding to...

Two of the sessions from day one of the 2023 European Conference on Interventional Oncology (ECIO; 16–19 April, Stockholm, Sweden) drew delegates’ focus to...

Sirtex Medical announced that the Brazilian National Agency of Supplementary Health (ANS) approved SIR-Spheres Y-90 resin microspheres for the treatment of intermediate- and advanced-stage hepatocellular...

ABK Biomedical has announced US Food and Drug Administration (FDA) 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous...

This advertorial is sponsored by PharmaCept. The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) recently incorporated transarterial chemoembolization with degradable starch microspheres (DSM-TACE) into...

Reto Bale (Medizinische Universität Innsbruck, Innsbruck, Austria) gave a presentation titled ‘Stereotactic thermal ablation—can it break the current limits?’ at the 2022 European Conference...

University Medical Center Utrecht (Utrecht, Netherlands) recently published the latest results from the HEPAR Primary study, which evaluated the safety and efficacy of Holmium-166...

Global Embolization Oncology Symposium Technologies (GEST; 19–22 May, New York, USA) provided delegates and faculty alike with the opportunity to hear about worldwide approaches...

TriSalus Life Sciences announced the enrolment of the first patient in its Pressure-Enabled Regional Immuno-Oncology (PERIO-02) clinical study in a press release.  The trial is...

NOTE: This video is ONLY available to watch in selected countries and geographies  Thierry De Baere (Villejuif, France) talks to Interventional News about the...

 Jon Bell (Manchester, UK) outlines the importance of standardisation of selective internal radiation therapy (SIRT) and how this rests on an advanced understanding of...

 The British Society for Interventional Radiology (BSIR) has set up an interventional radiology (IR) registry to capture a glimpse of the scope, breadth and...

Using selective internal radiation therapy (SIRT) to down-stage hepatocellular carcinoma (HCC) tumours or act as a bridge to surgery is feasible for both small...

This article is sponsored by Terumo Interventional Systems. Holmium-166 (166Ho) radioembolization is a safe treatment option for patients with hepatocellular carcinoma (HCC), show results from...

The first patient has been enrolled in DOORwaY-90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres Y-90...

The US Food and Drug Administration (FDA) have approved the DOORwaY90 study, a trial evaluating the safety and efficacy of selective internal radiation therapy...

Delineating the path towards personalised dosimetry in order to “maximise response to therapy”, David McNiel (University of Arizona Health Sciences, Tucson, USA) presented clinical...

The US Food and Drug Administration (FDA) have granted approval of the TheraSphere Y-90 glass microspheres (Boston Scientific), developed for the treatment of patients...

The National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of selective internal radiation therapy (SIRT) for the treatment...

“Our solution to the limitations of ethanol ablation is the polymer ethyl cellulose,” Erika Chelales (Center for Global Women’s Health Technologies, Duke University, Durham,...

The sustained release of anthracyclines and durable embolization from LifePearl microspheres (Terumo Europe) makes transarterial chemoembolization (TACE) with these embolic agents a safe and...

The Society of Interventional Oncology (SIO) and Boston Scientific have announced a new multicentre, prospective, randomised trial to study combination therapy of radioembolization and...

As presented at the Global Embolization Oncology Symposium Technologies (GEST) 2020 meeting (4–6 September, virtual), Robert Lewandowski discusses the evolution of radioembolization with Yttrium-90...

Guerbet has announced the registration of Vectorio, a kit for imaging hepatocellular carcinoma (HCC), in Canada. The kit consists of a set of Lipiodol-resistant medical...

TriSalus Life Sciences (“TriSalus”, formerly Surefire Medical) today announced the launch of its TriNav infusion system (“TriNav”). Powered by its proprietary pressure-enabled drug delivery...

Transarterial chemoembolization using microspheres appears to show “much better outcomes” than those seen with conventional TACE, both in the setting of hepatocellular carcinoma (HCC)...

A new indication for Lipiodol Ultra Fluid (Guerbet) has been approved in Switzerland and in India for chemoembolization (cTACE) of tumours in adults with...

The lessons learned from a recent research article were outlined in a presentation by interventional radiologist Maxime Ronot (Beaujon University Hospital, Paris, France) at...

Jens Ricke (Department of Radiology, University Hospital LMU Munich, Germany) presented the latest evidence about Y-90 radioembolization in hepatocellular carcinoma (HCC) at the 2019...

Patients have a strong preference for transradial access, a recent study published in the Journal of Vascular and Interventional Radiology finds. Lead author Lisa...

Multi-probe stereotactic radiofrequency ablation (SRFA) with intraprocedural image fusion represents an efficient minimally invasive therapy for hepatocellular carcinoma (HCC), even with tumour sizes larger...

Treating hepatocellular carcinoma (HCC) with microwave ablation is safe in the elderly population, the first study investigating the efficacy and safety profile of this...

Percutaneous CT-guided radiofrequency thermal ablation is a safe and effective alternative treatment option in patients with pulmonary metastases from hepatocellular carcinoma (HCC) that cannot...

Roche has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab)...

Multidisciplinary oncology thought leaders discuss the personalisation of SIRT, new and recent evidence for the minimally invasive procedure over sorafenib in advanced HCC, the...

Transarterial chemoembolization (TACE) using LifePearl (Terumo) drug-eluting embolic agents in the treatment of hepatocellular carcinoma has just been published.

Transarterial chemoembolization (TACE) is a mainstay of locoregional treatment for hepatocellular carcinoma (HCC) in the intermediate stage. “The technique for this procedure, however, continues...

Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.

Guerbet has announced a partnership with the Department of Radiodiagnosis and Interventional Radiology of Lausanne's University Hospital (CHUV) and the Lausanne Center for Experimental...

This approval also expands the number of chemotherapeutic drugs that can be loaded onto LifePearl to include idarubicin and epirubicin, a press release from...

BTG has announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere, Northwestern University, Illinois, USA, has adopted Y-90...

A prospective randomised controlled study that compared outcomes between hepatocellular carcinoma patients who were treated by microwave ablation with those who were treated by...

“While both radial and femoral accesses are safe and effective for transarterial liver embolization, it is clear that the patients prefer radial access,” said Marcelo Guimaraes, Charleston, USA, who was presenting on the...

A randomised, double-blind, placebo-controlled trial evaluating the efficacy of prophylactic dexamethasone in preventing the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in...

Guerbet has announced that the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM; The German Federal Institute for Drugs and Medical Devices) has now approved Lipiodol...

The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...

Surefire, the developer of site-specific delivery devices for the interventional oncology market, has announced the first closing of a US$12.8 M Series D financing...

Sirtex has announced that the SARAH (Sorafenib vs. radioembolisation in advanced hepatocellular carcinoma) randomised controlled study results will be presented at the upcoming European...